Insider Purchases: Inside the Buy

Tag: risks investing in bhvn

Colorful illustration of Biohaven’s CEO and directors dropping glowing dollar bills into a three-chamber biotech machine labeled ‘Epilepsy,’ ‘Obesity,’ and ‘IgA Nephropathy,’ while an FDA storm cloud hovers overhead but an angel floats above the pipeline.

Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel

Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.

Read entire article

Tags: BHVN, Biohaven, Biotech Investing, Biotech Stocks, buy or sell bhvn, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, Clinical Trials, Dr. Vlad Coric, fda news, funanc1al, funanc1al humor, immunology, insider buying, neuroscience, rare diseases, risks investing in bhvn, speculative stocks, why invest in bhvn